延伸閱讀網址

前言
Flaviviruses are vector-borne RNA viruses that can potentially cause a variety of severe diseases in humans, impacting an estimated 400 million people annually. Flaviviruses are often carried by arthropods such as ticks and mosquitoes, with more than a quarter of the world’s population living in areas where mosquito-borne flaviviruses are considered endemic.
Due to climate change, globalization, and urbanization, the incidence of flaviviruses is increasing worldwide. Rising temperatures may intensify flavivirus diseases in already endemic areas through faster viral amplification, increased vector survival, and higher reproduction and biting rates.
There are currently no specific treatments available for flavivirus diseases and few vaccines are available to prevent them, highlighting the need for novel therapies aiming to tackle these emerging health threats.
Aligned to the opening of the new J&J Satellite Center for Global Health Discovery at the Duke–NUS Medical School (Duke-NUS) in Singapore, Johnson & Johnson Innovation, together with Johnson & Johnson Global Public Health, is proud to launch the Global Health Discovery QuickFire Challenge: Flavivirus Infections. Innovators from across the Asia Pacific and Oceania regions1 are invited to submit potentially ground-breaking ideas aiming to treat, control, or prevent flavivirus disease.
The innovator(s) with the best potential solution will receive grant funding from a total pool of up to $300,000, access to the Johnson & Johnson Innovation – JLABS Asia Pacific community, including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts at the Johnson & Johnson Family of Companies.
黃病毒是媒介傳播的 RNA 病毒，可能導致人類多種嚴重疾病，估計每年影響 4 億人。黃病毒通常由蜱蟲和蚊子等節肢動物攜帶，世界上超過四分之一的人口生活在蚊媒黃病毒流行的地區。

由於氣候變化、全球化和城市化，黃病毒的發病率在世界範圍內不斷增加。通過更快的病毒擴增、增加的載體存活率以及更高的繁殖和叮咬率，氣溫升高可能會加劇已經流行地區的黃病毒病。

目前還沒有針對黃病毒病的特定治療方法，也沒有什麼疫苗可以預防這些疾病，這突出表明需要新的療法來應對這些新出現的健康威脅。

為配合新加坡杜克-新加坡國立大學醫學院 (Duke-NUS) 新的強生全球健康發現衛星中心的開幕，強生創新與強生全球公共衛生部自豪地推出全球健康Discovery QuickFire 挑戰：黃病毒感染。來自亞太和大洋洲地區1的創新者受邀提交旨在治療、控製或預防黃病毒病的潛在突破性想法。

擁有最佳潛在解決方案的創新者將獲得總額高達 300,000 美元的贈款資金，進入強生創新 – JLABS 亞太社區，包括在 JLABS @ 上海為期一年的專用工作站，以及指導來自 Johnson & Johnson Family of Companies 的專家。

活動主題
We are interested in potentially ground-breaking ideas aiming to treat, control, or prevent flavivirus disease, such as:
Exploratory therapeutic platform technologies targeting the genus Flavivirus (or Flavivirdae family)
Broad-spectrum therapeutics/antiviral modalities targeting viral replication of flaviviruses (dengue virus, Zika virus, West Nile virus, Japanese Encephalitis virus, yellow fever virus)
Immune-mediated approaches such as host-directed targets aiming to control flavivirus infections
Disease learning: understanding underlying mechanism of flavivirus pathogenesis
Novel approaches toward patient identification and stratification that can include:
Multidimensional biomarker discovery platforms, including those with AI/ML based analytics
Deep patient clinical and molecular phenotyping data sets
Enabling technologies for clinical trials:
Potential solutions aiming to identify and recruit specific patient sub-populations
我們對旨在治療、控製或預防黃病毒病的潛在突破性想法感興趣，例如：

針對黃病毒屬（或黃病毒科）的探索性治療平台技術
針對黃病毒（登革熱病毒、寨卡病毒、西尼羅河病毒、日本腦炎病毒、黃熱病病毒）的病毒複製的廣譜治療/抗病毒方式
免疫介導的方法，例如旨在控制黃病毒感染的宿主導向目標
疾病學習：了解黃病毒發病機制的潛在機制
患者識別和分層的新方法包括：

多維生物標誌物發現平台，包括那些具有基於 AI/ML 的分析的平台
深度患者臨床和分子表型數據集
臨床試驗的使能技術：

旨在識別和招募特定患者亞群的潛在解決方案
參賽資格
Applicants must have a physical presence in Asia, Australia, or Oceania.
申請人必須在亞洲、澳大利亞或大洋洲有實際存在。

活動時程
June 21, 2022:Launch
January 13, 2023:Deadline
2023:Award Announcement
2022 年 6 月 21 日：發布
2023 年 1 月 13 日：截止日期
2023：獲獎公告
報名方式
You will have the opportunity and are encouraged to upload supporting materials such as non-confidential slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes. Make sure that you do not submit any information that is non-proprietary or owned by a third party.
作為申請的一部分，您將有機會並被鼓勵上傳支持材料，例如非機密幻燈片、研究論文和視頻。 您可以連同輸入的回復一起提交視頻。 最大長度為 2 分鐘。 確保您不提交任何非專有或第三方擁有的信息。

評分標準
Potential impact on human health
Uniqueness and level of innovation of the idea
Feasibility of the idea and potential path to commercialization
Thoroughness of approach
Identification of key resources and plan to further ideate
Rapid implementation and deployability with the potential to reach patients in communities most vulnerable to flavivirus diseases
對人類健康的潛在影響
想法的獨特性和創新水平
想法的可行性和商業化的潛在途徑
方法的徹底性
確定關鍵資源併計劃進一步構思
快速實施和部署，有可能覆蓋最易感染黃病毒病的社區患者
活動獎勵
Grant funding from a total pool of$300,000
Access to the Johnson & Johnson Innovation – JLABS Asia Pacific community, including a dedicated workstation for one year at JLABS @ Shanghai
Mentorship from experts at the Johnson & Johnson Family of Companies*
從 300,000 美元的總資金池中撥款
訪問強生創新 – JLABS 亞太社區，包括在 JLABS @ 上海一年的專用工作站
來自強生集團公司專家的指導*
聯絡方式
主辦單位：Johnson & Johnson Innovation
聯絡人：Johnson & Johnson Innovation
聯絡人信箱：jnjinnovation@its.jnj.com
https://jnjinnovation.com/innovation-challenges/global-health-discovery-quickfire-challenge-flavivirus-infections